Clinical, serological and treatment differences between pre and post BLM treatment
| VB (pre opBLM) | V6M (post opBLM) | V12M (post opBLM) | |
|---|---|---|---|
| SLEDAI, median (p25-p75) | 0 (0–2) | 2 (0–49) | 0 (0–2) |
| PGA (0–3), median (p25-p75) | 0.33 (0–0,5) | 0.28 (0–0,48) | 0.2 (0–0.4) |
| Remission DORIS, N/total (%) | 15/26 (57.7%) | 14/22 (63.6%) | 12/19 (63.2%) |
| LLDAS, N/total (%) | 23/26 (88.5%) | 20/22(90.9%) | 17/19(89.5%) |
| CRP, median (p25-p75) | 1.65 (0.4–5.5) | 1.63(0.46–4.14) | 0.7(0.25–3.9) |
| C3 or C4 low, N/total (%) | 5/26(19.2%) | 11/25(44%) # | 7/20(35%) # |
| Anti-DNA antibodies, N/total (%) | 5/26(19.2%) | 2/24(8.3%) | 0/20(0%) |
| Active serology *, N/total (%) | 8/29(27.6%) | 13/24(54.2%) | 7/20(35%) |
| DMARDs, N/total (%) | 17/26(65.4%) | 14/25(56%) | 10/20(50%) |
| Patients on GC, N/total (%) | 15/26(57.7%) | 12/24(50%) | 8/20(40%) # |
| GC dose, median (p25-p75) | 2.5 (0–5) | 2.5 (0–5) # | 1.25 (0–5) # |
SLEDAI: Systemic Lupus Erythematosus Disease Activity Index
PGA: Physician Global Assessment
LLDAS: Lupus Low Disease Activity State
DMARDs: Disease-modifying anti-rheumatic drugs
GC: Glucocorticoids. CRP: C Reactive Protein. * Active serology means complements and or anti-DNA